Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Elena Torrisi"'
Autor:
Maria Teresa Bruno, Giuseppe Caruso, Elena Torrisi, Raffaela Grimaldi, Biagio Abate, Francesco Saverio Luciani, Susanna Basile, Marco Marzio Panella
Publikováno v:
Diagnostics, Vol 14, Iss 9, p 911 (2024)
The aim of the study was to assess sexual health in women who underwent Loop Electrosurgical Excisional Procedure (LEEP) for the treatment of cervical intraepithelial neoplasia 3 (CIN 3). One hundred thirty-one women were enrolled, and the Female Sex
Externí odkaz:
https://doaj.org/article/24783a87f682418391290744ea7bec79
Autor:
Juan J. Rojas, Elena Torrisi, Maryne A. J. Dubois, Riashat Hossain, Andrew J. P. White, Giovanni Zappia, James J. Mousseau, Chulho Choi, James A. Bull
Annulations that combine di-acceptors with bis-nucleophiles are uncommon. Here, we report the synthesis of 1,4-dioxanes from 3-aryloxetan-3-ols, as 1,2-bis-electrophiles, and 1,2-diols. Brønsted acid Tf2NH catalyzes both the selec-tive activation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a08f69cc2076a2007a0dd278d4ca80da
http://hdl.handle.net/10044/1/96039
http://hdl.handle.net/10044/1/96039
Autor:
Paola Di Nardo, Silvio Ken Garattini, Elena Torrisi, Valentina Fanotto, Gianmaria Miolo, Angela Buonadonna, Fabio Puglisi
Publikováno v:
Cancers. 14:1502
Small bowel adenocarcinoma (SBA) is a rare disease for which scarce evidence is available. We summarized data available on systemic treatment of advanced SBA. Methods: Scientific literature was evaluated to find phase II or phase III clinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50563fef23880c74e5507920266ef9cb
https://doi.org/10.3390/cancers14061502
https://doi.org/10.3390/cancers14061502
Autor:
Gianmaria Miolo, Fabio Puglisi, C.A. Bertuzzi, Silvio Ken Garattini, Michele Bartoletti, Lorenzo Gerratana, Giacomo Pelizzari, C. Lisanti, C. Corvaja, Debora Basile, M. Borghi, Michela Guardascione, Elena Torrisi, L. Da Ros, Valentina Fanotto, Angela Buonadonna, F. Fabiani, P. Di Nardo, L. Bortot
Publikováno v:
Nutrition. 65:1-2
Overweight is an established risk factor of the colorectal cancer initiation and progression. Aim of this study is to investigate the prognostic role of visceral fat (VAT) in metastatic colorectal cancer (MCRC). We retrospectively analyzed 71 consecu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2be9850f2b9da60955f268d1d35af349
https://doi.org/10.1016/j.nut.2019.08.003
https://doi.org/10.1016/j.nut.2019.08.003
Publikováno v:
Personalized Management of Breast Cancer. :120-131
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f78838a0e5eeaa2ba65c36d9d904921b
https://doi.org/10.2217/ebo.13.409
https://doi.org/10.2217/ebo.13.409
Autor:
G. Aprile, Mattia Garutti, P. Di Nardo, Angela Buonadonna, S. Buriolla, G. Curtolo, B. Michele, Silvio Ken Garattini, Giovanni Gerardo Cardellino, Elena Torrisi, Fabio Puglisi, Lorenzo Gerratana, Debora Basile, L. Da Ros, Marta Bonotto, Nicoletta Pella, Elena Ongaro, C. Corvaja, Gianmaria Miolo, L. Bortot, Giacomo Pelizzari, C. Lisanti
Publikováno v:
Annals of Oncology. 30:iv79
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa799e6e542f728edbf83b096a83c76b
https://doi.org/10.1093/annonc/mdz155.287
https://doi.org/10.1093/annonc/mdz155.287
Autor:
Giacomo Pelizzari, Gianmaria Miolo, C. Lisanti, C. Corvaja, Debora Basile, Lorenzo Gerratana, Paola Di Nardo, Gianluca Curtolo, Michele Bartoletti, Mattia Garutti, Simon Spazzapan, Silvana Saracchini, Lucia Da Ros, Andrea Freschi, L. Bortot, S. Buriolla, Elena Torrisi, Silvia Bolzonello, Silvio Ken Garattini, Fabio Puglisi
Publikováno v:
Journal of Clinical Oncology. 37:577-577
577 Background: It is matter of current debate which would be the best chemotherapy backbone of neoadjuvant HER2-targeted therapy for HER2+ BC. The TRAIN 2 trial showed no significant difference in terms of pathological complete response (pCR) when a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85a25739ef1ae405e045886752ac2a0f
https://doi.org/10.1200/jco.2019.37.15_suppl.577
https://doi.org/10.1200/jco.2019.37.15_suppl.577
Autor:
Luisa Foltran, Angela Buonadonna, Stefano Merigliano, Renato Cannizzaro, Roberto Innocente, Eleonora Fort, Dino Tonin, Francesca Bergamo, Sara Lonardi, Vincenzo Canzonieri, G. Bertola, Elena Torrisi, E. Palazzari, Antonino De Paoli, Jerry Polesel, Claudio Bellucco, Sara Galuppo, Salvatore Pucciarelli, F. Navarria, Paolo Ubiali
Publikováno v:
Journal of Clinical Oncology. 37:4066-4066
4066 Background: This study evaluates the feasibility, safety and efficacy of a trimodality treatment, with surgery postponed after neoadjuvant chemotherapy (CT) and chemoradiotherapy (CRT), in LAGC. Methods: Patients (pts) with cT3-4 and/or N+ LAGC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f8ce0181b5d8ab4f95374aea2f8f345
https://doi.org/10.1200/jco.2019.37.15_suppl.4066
https://doi.org/10.1200/jco.2019.37.15_suppl.4066
Autor:
Davide Lombardi, Gustavo Baldassarre, Silvio Ken Garattini, Fabio Puglisi, Giorgio Giorda, Giacomo Pelizzari, C. Lisanti, Mattia Garutti, Simona Scalone, Lucia Da Ros, Elena Torrisi, Silvia Bolzonello, Milena S. Nicoloso, Roberto Sorio, L. Bortot, Lorenzo Gerratana, Michele Bartoletti, Debora Basile, Paola Di Nardo, C. Corvaja
Publikováno v:
Journal of Clinical Oncology. 37:5564-5564
5564 Background: Patients (pts) experiencing a PS rOC are generally re-exposed to a platinum based-chemotherapy (CT). In this setting, the addition of a targeted agent like bevacizumab (BEV) or PARP inhibitors (PARPi) as concomitant and/or maintenanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acf9322f1187c4b3b7fb785c4b66197e
https://doi.org/10.1200/jco.2019.37.15_suppl.5564
https://doi.org/10.1200/jco.2019.37.15_suppl.5564
Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients
Autor:
Giuseppe Toffoli, Angela Buonadonna, Sergio Frustaci, Gianna Tabaro, Salvatore Tumolo, Giovanni Lo Re, Elisa Turchet, Elena Torrisi, Gianmaria Miolo, Giuseppe Corona
Publikováno v:
International Journal of Clinical Oncology. 18:510-516
A combination of docetaxel (D), oxaliplatin (O), and capecitabine (C) (DOC) was studied in this dose-escalation phase Ib trial in patients with untreated advanced gastric cancer. Dose-limiting toxicity (DLT) included any grade 4 hematological or any
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::820e1c8674f7a8df8bced6fca976a544
https://doi.org/10.1007/s10147-012-0410-z
https://doi.org/10.1007/s10147-012-0410-z